المؤلفون: M. D. Ter-Ovanesov, D. M. Yagudaev, A. A. Gritskevich, A. V. Umyarova, V. A. Bezhenar, М. Д. Тер-Ованесов, Д. М. Ягудаев, А. А. Грицкевич, А. В. Умярова, В. А. Беженар

المصدر: Research and Practical Medicine Journal; Том 11, № 1 (2024); 70-77 ; Research'n Practical Medicine Journal; Том 11, № 1 (2024); 70-77 ; 2410-1893 ; 10.17709/2410-1893-2024-11-1

مصطلحات موضوعية: муцинозная аденокарцинома урахуса, resection of the bladder, mucinous adenocarcinoma of urachus, резекция мочевого пузыря

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/916/613Test; Loizzo D, Pandolfo SD, Crocerossa F, Guruli G, Ferro M, Paul AK, et al. Current Management of Urachal Carcinoma: An Evidence-based Guide for Clinical Practice. Eur Urol Open Sci. 2022 Mar 14;39:1–6. https://doi.org/10.1016/j.euros.2022.02.009Test; Bruins HM, Visser O, Ploeg M, Hulsbergen-van de Kaa CA, Kiemeney LA, Witjes JA. The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol. 2012 Oct;188(4):1102–1107. https://doi.org/10.1016/j.juro.2012.06.020Test; Нюшко К. М., Алексеев Б. Я., Каприн А. Д. Клиническое наблюдение органосохраняющего хирургического лечения больного раком урахуса. Медицинский альманах. 2015;2(37):53–57.; Kim IK, Lee JY, Kwon JK, Park JJ, Cho KS, Ham WS, et al. Prognostic factors for urachal cancer: a bayesian model-averaging approach. Korean J Urol. 2014 Sep;55(9):574–580. https://doi.org/10.4111/kju.2014.55.9.574Test; Щедров Д. Н., Шорманов И. С., Котов С. В., Морозов Е. В. Диагностика и лечение заболеваний, обусловленных аномалиями облитерации урахуса у детей. М.: Издательство «Перо»; 2021, 107 с.; Claps M, Stellato M, Zattarin E, Mennitto A, Sepe P, Guadalupi V, et al. Current Understanding of Urachal Adenocarcinoma and Management Strategy. Curr Oncol Rep. 2020 Jan 27;22(1):9. https://doi.org/10.1007/s11912-020-0878-zTest; Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol. 1984 Jan;131(1):1–8. https://doi.org/10.1016/s0022-5347Test(17)50167-6; Ashley RA, Inman BA, Sebo TJ, Leibovich BC, Blute ML, Kwon ED, Zincke H. Urachal carcinoma: clinicopathologic features and longterm outcomes of an aggressive malignancy. Cancer. 2006 Aug 15;107(4):712–720. https://doi.org/10.1002/cncr.22060Test; Pinthus JH, Haddad R, Trachtenberg J, Holowaty E, Bowler J, Herzenberg AM, et al. Population based survival data on urachal tumors. J Urol. 2006 Jun;175(6):2042–2047; discussion 2047. https://doi.org/10.1016/s0022-5347Test(06)00263-1; Shao G, Xu C, Liu J, Li X, Li L, Li X, et al. Clinical, Pathological, and Prognostic Analysis of Urachal Carcinoma. Urol Int. 2022;106(2):199–208. https://doi.org/10.1159/000518028Test; Szarvas T, Módos O, Niedworok C, Reis H, Szendröi A, Szász MA, Nyirády P. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Urol Oncol. 2016 Sep;34(9):388–398. https://doi.org/10.1016/j.urolonc.2016.04.012Test; Helsby R. Ruptured infected urachal cyst. Br Med J. 1955 Sep 3;2(4939):603. https://doi.org/10.1136/bmj.2.4939.603Test; Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec;46(12):1808–1814. https://doi.org/10.1016/j.humpath.2015.07.021Test; Cinar NB, Yilmaz H, Avci IE, Cakmak K, Teke K, Dillioglugil O. Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria. World J Surg Oncol. 2023 Feb 23;21(1):58. https://doi.org/10.1186/s12957-023-02943-9Test; Mayr R, Fritsche HM, Pycha A, Pycha A. Radical cystectomy and the implications of comorbidity. Expert Rev Anticancer Ther. 2014 Mar;14(3):289–295. https://doi.org/10.1586/14737140.2014.868775Test; Duan F, Zhai W, Zhang B, Guo S. Urachal carcinoma: Impact of recurrence pattern and lymphadenectomy on long-term outcomes. Cancer Med. 2020 Jun;9(12):4166–4174. https://doi.org/10.1002/cam4.3059Test; Нюшко К. М., Алексеев Б. Я., Калпинский А. С., Каприн А. Д. Рак урахуса. Онкология. Журнал им. П. А. Герцена. 2015;4(3):43–47.; Кунафина Р. И., Сакаева Д. Д., Урманцев М. Ф., Сулейманова Р. Р. Клинический случай применения комбинации паклитаксела и карбоплатина в терапии метастатической опухоли урахуса. Фарматека. 2020;27(11):73–76. https://doi.org/10.18565/pharmateca.2020.11.73-76Test; https://www.rpmj.ru/rpmj/article/view/916Test

الإتاحة: https://doi.org/10.17709/2410-1893-2024-11-1-6Test
https://doi.org/10.17709/2410-1893-2024-11-1Test
https://doi.org/10.1016/j.euros.2022.02.009Test
https://doi.org/10.1016/j.juro.2012.06.020Test
https://doi.org/10.4111/kju.2014.55.9.574Test
https://doi.org/10.1007/s11912-020-0878-zTest
https://doi.org/10.1016/s0022-5347Test(17)50167-6
https://doi.org/10.1002/cncr.22060Test
https://doi.org/10.1016/s0022-5347Test(06)00263-1
https://doi.org/10.1159/000518028Test

المؤلفون: V. A. Oganyan, A. D. Simonov, N. A. Karelskaya, A. G. Kochetov, D. M. Monakov, А. A. Gritskevich, В. А. Оганян, А. Д. Симонов, Н. А. Карельская, А. Г. Кочетов, Д. М. Монаков, А. А. Грицкевич

المساهمون: The study was not sponsored, Исследование не имело спонсорской поддержки

المصدر: Urology Herald; Том 11, № 2 (2023); 203-214 ; Вестник урологии; Том 11, № 2 (2023); 203-214 ; 2308-6424 ; 10.21886/2308-6424-2023-11-2

مصطلحات موضوعية: уретерокутанеостома, cystectomy, robot-assisted cystectomy, intracoporal urinary diversion, extracorporeal urinary diversion, Studer operation, Bricker operation, ureterocutaneostomy, цистэктомия, робот-ассистированная цистэктомия, интракопоральное отведение мочи, эктракорпоральное отведение мочи, операция Штудера, операция Брикера

وصف الملف: application/pdf

العلاقة: https://www.urovest.ru/jour/article/view/735/481Test; Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017;198(3):552-559. Erratum in: J Urol. 2017;198(5):1175. DOI:10.1016/j.juro.2017.04.086; Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016;196(4):1021-9. DOI:10.1016/j.juro.2016.06.049; Gul ZG, Katims AB, Winoker JS, Wiklund P, Waingankar N, Mehrazin R. Robotic assisted radical cystectomy versus open radical cystectomy: a review of what we do and don't know. Transl Androl Urol. 2021;10(5):2209-2215. DOI:10.21037/tau.2019.11.32; Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018;391(10139):2525-2536. DOI:10.1016/S0140-6736(18)30996-6; Menon M, Hemal AK, Tewari A, Shrivastava A, Shoma AM, Abol-Ein H, Ghoneim MA. Robot-assisted radical cystectomy and urinary diversion in female patients: technique with preservation of the uterus and vagina. J Am Coll Surg. 2004;198(3):386-93. DOI:10.1016/j.jamcollsurg.2003.11.010; Beecken WD, Wolfram M, Engl T, Bentas W, Probst M, Blaheta R, Oertl A, Jonas D, Binder J. Robotic-assisted laparoscopic radical cystectomy and intra-abdominal formation of an orthotopic ileal neobladder. Eur Urol. 2003;44(3):337-9. DOI:10.1016/s0302-2838(03)00301-4; Клинические рекомендации «Рак мочевого пузыря». Ссылка активна на 09.12.2022. https://oncology-association.ru/wp-content/uploads/2022/03/rak-mochevogo-puzyrya.pdfTest; Hirobe M, Tanaka T, Shindo T, Ichihara K, Hotta H, Takahashi A, Kato R, Yanase M, Matsukawa M, Itoh N, Kunishima Y, Taguchi K, Horita H, Masumori N. Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan. Int J Clin Oncol. 2018;23(4):734-741. DOI:10.1007/s10147-018-1245-z; Lee CU, Kang M, Kim TJ, Na JP, Sung HH, Jeon HG, Seo SI, Jeon SS, Lee HM, Jeong BC. Predictors of postoperative complications after robot-assisted radical cystectomy with extracorporeal urinary diversion. Cancer Manag Res. 2019;11:5055-5063. DOI:10.2147/CMAR.S199432; Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, Coleman JA, Mathew S, Vickers A, Schnorr GC, Feuerstein MA, Rapkin B, Parra RO, Herr HW, Laudone VP. Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. Eur Urol. 2015;67(6):1042-1050. DOI:10.1016/j.eururo.2014.11.043; Wijburg CJ, Hannink G, Michels CTJ, Weijerman PC, Issa R, Tay A, Decaestecker K, Wiklund P, Hosseini A, Sridhar A, Kelly J, d'Hondt F, Mottrie A, Klaver S, Edeling S, Dell'Oglio P, Montorsi F, Rovers MM, Witjes JA. Learning Curve Analysis for Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section Scientific Working Group. Eur Urol Open Sci. 2022;39:55-61. DOI:10.1016/j.euros.2022.03.004; Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-13. DOI:10.1097/01.sla.0000133083.54934.ae; Borghesi M, Schiavina R, Antonelli A, Buizza C, Celia A, Parma P, De Concilio B, Mengoni F, Romagnoli D, Saraceni G, Brunocilla E, Porreca A. Peri-Operative Outcomes after Open and Robot-Assisted Radical Cystectomy by Using an Advanced Bipolar Seal and Cut Technology (Caiman®): A Prospective, Comparative, and Multi-Institutional Study. Curr Urol. 2019;12(2):64-69. DOI:10.1159/000489421; Chang SS, Smith JA Jr, Wells N, Peterson M, Kovach B, Cookson MS. Estimated blood loss and transfusion requirements of radical cystectomy. J Urol. 2001;166(6):2151-4. PMID: 11696725.; Оганян В.А., Грицкевич А.А., Симонов А.Д., Полотбек Ж., Мирошкина И.В., Костин А.А. Робот-ассистированная цистэктомия с ортотопической везикопластикой при раке мочевого пузыря. Экспериментальная и клиническая урология. 2022;15(3)44-54 DOI:10.29188/2222-8543-2022-15-3-44-54; https://www.urovest.ru/jour/article/view/735Test

الإتاحة: https://doi.org/10.21886/2308-6424-2023-11-2-203-214Test
https://doi.org/10.21886/2308-6424-2023-11-2Test
https://doi.org/10.1016/j.juro.2017.04.086Test
https://doi.org/10.1016/j.juro.2016.06.049Test
https://doi.org/10.21037/tau.2019.11.32Test
https://doi.org/10.1016/S0140-6736Test(18)30996-6
https://doi.org/10.1016/j.jamcollsurg.2003.11.010Test
https://doi.org/10.1016/s0302-2838Test(03)00301-4
https://doi.org/10.1007/s10147-018-1245-zTest
https://doi.org/10.2147/CMAR.S199432Test

المؤلفون: A. V. Chupin, N. R. Masalimov, T. P. Baitman, A. A. Gritskevich, V. A. Kulbak, I. V. Miroshkina, E. V. Kondratyev, Ya. A. Stepanova, I. E. Timina, А. В. Чупин, Н. Р. Масалимов, Т. П. Байтман, А. А. Грицкевич, В. А. Кульбак, И. В. Мирошкина, Е. В. Кондратьев, Ю. А. Степанова, И. Е. Тимина

المصدر: Research and Practical Medicine Journal; Том 10, № 4 (2023); 119-131 ; Research'n Practical Medicine Journal; Том 10, № 4 (2023); 119-131 ; 2410-1893 ; 10.17709/2410-1893-2023-10-4

مصطلحات موضوعية: экстракорпоральная резекция, renal cell carcer, kidney cancer, kidney resection, simultaneous surgery, pharmaco-cold ischemia, extracorporeal resection, почечно-клеточный рак, рак почки, резекция почки, симультанная операция, фармако-холодовая ишемия

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/934/597Test; https://www.rpmj.ru/rpmj/article/view/934/607Test; Kenyon J, Liu W, Dalgleish A. Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. Anticancer Res. 2018 Oct;38(10):5831–5835. https://doi.org/10.21873/anticanres.12924Test; Onohara T, Kyuragi R, Inoue K, Yoshida S, Matsumoto T, Furuyama T. Late-Onset Malignant Neoplasms and Their Prognostic Factors after Abdominal Aortic Aneurysm Repair. Ann Vasc Surg. 2019 Apr;56:194–201. https://doi.org/10.1016/j.avsg.2018.08.095Test; Oliveiar-Pinto J, Mosquera N, Vidoedo J, Moreira-Sampaio S, Teixeira J. Co-existence of Abdominal Aortic Aneurysm with Urologic Neoplasm: Which Should Be Treated First in the Endovascular Era? Rev Port Cir Cardiotorac Vasc. 2017 Jul-Dec;24(3-4):187.; von Meijenfeldt GCI, Alberga AJ, Balm R, Vahl AC, Verhagen HJM, Blankensteijn JD, et al. Results from a nationwide prospective registry on open surgical or endovascular repair of juxtarenal abdominal aortic aneurysms. J Vasc Surg. 2022 Jan;75(1):81–89.e5. https://doi.org/10.1016/j.jvs.2021.06.031Test; Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA, Mansour MA, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018 Jan;67(1):2–77.e2. https://doi.org/10.1016/j.jvs.2017.10.044Test; Calero A, Illig KA. Overview of aortic aneurysm management in the endovascular era. Semin Vasc Surg. 2016 Mar;29(1-2):3–17. https://doi.org/10.1053/j.semvascsurg.2016.07.003Test; Keisler B, Carter C. Abdominal aortic aneurysm. Am Fam Physician. 2015 Apr 15;91(8):538–543; Clancy K, Wong J, Spicher A. Abdominal Aortic Aneurysm: A Case Report and Literature Review. Perm J. 2019;23:18.218. https://doi.org/10.7812/tpp/18.218Test; United Kingdom EVAR Trial Investigators; Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D, Sculpher MJ. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med. 2010 May 20;362(20):1863–1871. http://doi.org/10.1056/nejmoa0909305Test; Galt SW, McCarthy WJ, Pearce WH, Carter MF, Dalton DP, Garnett JE, et al. Simultaneous abdominal aortic aneurysm repair and nephrectomy for neoplasm. Am J Surg. 1995 Aug;170(2):227–230. https://doi.org/10.1016/s0002-9610Test(99)80292-x; Kira S, Sawada N, Kudou S, Zakoji H, Kaga S, Matsumoto M, Takeda M. Successful staged management of simultaneous abdominal aortic aneurysm and renal tumor: the novel minimally invasive treatment with endovascular aneurysm repair and retroperitoneal laparoscopic radical nephrectomy in an elderly and high-risk case. Clin Pract. 2012 Apr 12;2(2):e45. https://doi.org/10.4081/cp.2012.e45Test; DeMasi RJ, Gregory RT, Snyder SO, Gayle RG, Parent FN, Wheeler JR. Coexistent abdominal aortic aneurysm and renal carcinoma: management options. Am Surg. 1994 Dec;60(12):961–966.; Pattaras JG, Milner R. Staged minimally invasive treatment of inflammatory abdominal aortic aneurysm and renal cell carcinoma. Can J Urol. 2009 Apr;16(2):4596–4598.; Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. Доступно по: https://gco.iarc.fr/todayTest. Дата обращения: 02.03.2020.; Состояние онкологической помощи населению России в 2020 году. Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 239 с. Доступно по: https://oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdfTest. Дата обращения: 01.11.2023.; Jongkind V, Yeung KK, Akkersdijk GJ, Heidsieck D, Reitsma JB, Tangelder GJ, Wisselink W. Juxtarenal aortic aneurysm repair. J Vasc Surg. 2010 Sep;52(3):760–767. https://doi.org/10.1016/j.jvs.2010.01.049Test; Peeters B, Moreels N, Vermassen F, van Herzeele I. Management of abdominal aortic aneurysm and concomitant malignant disease. J Cardiovasc Surg (Torino). 2019 Aug;60(4):468–475. https://doi.org/10.23736/s0021-9509.19.10946-9Test; Давыдов М. И., Акчурин Р. С., Герасимов С. С., Дземешкевич С. Л., Бранд Я. Б., Долгов И. М., Шестопалова И. М. Сочетанное хирургическое лечение онкологических больных с конкурирующими сердечно-сосудистыми заболеваниями при опухолевых поражениях легких и средостения. Хирургия. Журнал им. Н.И. Пирогова. 2010;(8):4–10.; Имаев Т. Э., Комлев А. Е., Акчурин Р. С. Хирургия сердца и сосудов у онкологических больных – новый вызов гибридной хирургии. Кардиоваскулярная терапия и профилактика. 2019;18(4):99–104. https://doi.org/10.15829/1728-8800-2019-4-99-104Test; Jibawi A, Ahmed I, El-Sakka K, Yusuf SW. Management of concomitant cancer and abdominal aortic aneurysm. Cardiol Res Pract. 2011 Apr 19;2011:516146. https://doi.org/10.4061/2011/516146Test; Szilagyi DE, Elliott JP, Berguer R. Coincidental malignancy and abdominal aortic aneurysm. Problems of management. Arch Surg. 1967 Sep;95(3):402–412. https://doi.org/10.1001/archsurg.1967.01330150078012Test; Porcellini M, Nastro P, Bracale U, Brearley S, Giordano P. Endovascular versus open surgical repair of abdominal aortic aneurysm with concomitant malignancy. J Vasc Surg. 2007 Jul;46(1):16–23. https://doi.org/10.1016/j.jvs.2006.09.070Test; Baxter NN, Noel AA, Cherry K, Wolff BG. Management of patients with colorectal cancer and concomitant abdominal aortic aneurysm. Dis Colon Rectum. 2002 Feb;45(2):165–170. https://doi.org/10.1007/s10350-004-6138-8Test; Cvetkovic S, Koncar I, Galun D, Ribac J, Markovic M, Ilic N, Dragas M, Davidovic L. Treatment of a Patient with Abdominal Aortic Aneurysm and Hepatocellular Carcinoma. Ann Vasc Surg. 2017 Apr;40:295.e1–295.e4. https://doi.org/10.1016/j.avsg.2016.07.075Test; Třeška V, Hora M, Certík B, Moláček J, Houdek K, Náhlík J, Stránský P. Jednodobý výkon u aneuryzmatu břišní aorty a renálního karcinomu [Simultaneous procedure in patients with abdominal aortic aneurysm and renal carcinoma]. Rozhl Chir. 2014 Aug;93(8):424–427. Czech.; Hafez KS, El Fettouh HA, Novick AC, Ouriel K. Management of synchronous renal neoplasm and abdominal aortic aneurysm. J Vasc Surg. 2000 Dec;32(6):1102–1110. https://doi.org/10.1067/mva.2000.111539Test; Toursarkissian B, Mejia A, Wholey MH, Lawler MA, Thompson IM, Sykes MT. Endovascular AAA repair in a patient with a horseshoe kidney and an isthmus mass. J Endovasc Ther. 2001 Dec;8(6):604–608. https://doi.org/10.1177/152660280100800613Test; Mozafar M, Zarrintan S, Tubbs RS. Simultaneous resection of abdominal aortic aneurysm and left renal cell carcinoma: A rare case and review of the literature. J Cardiovasc Thorac Res. 2020;12(2):152–155. https://doi.org/10.34172/jcvtr.2020.26Test; Lawrie K, Whitley A, Balaz P. A systematic review and meta-analysis on the management of concomitant abdominal aortic aneurysms and renal tumours. Vascular. 2022 Aug;30(4):661–668. https://doi.org/10.1177/17085381211026827Test; https://www.rpmj.ru/rpmj/article/view/934Test

الإتاحة: https://doi.org/10.17709//2410-1893-2023-10-4-10Test
https://doi.org/10.17709/2410-1893-2023-10-4Test
https://doi.org/10.21873/anticanres.12924Test
https://doi.org/10.1016/j.avsg.2018.08.095Test
https://doi.org/10.1016/j.jvs.2021.06.031Test
https://doi.org/10.1016/j.jvs.2017.10.044Test
https://doi.org/10.1053/j.semvascsurg.2016.07.003Test
https://doi.org/10.7812/tpp/18.218Test
https://doi.org/10.1056/nejmoa0909305Test
https://doi.org/10.1016/s0002-9610Test(99)80292-x

المؤلفون: A. A. Gritskevich, T. P. Baitman, S. V. Mishugin, A. Yu. Popov, D. M. Yagudaev, L. A. Falaleeva, I. G. Rusakov, А. А. Грицкевич, Т. П. Байтман, С. В. Мишугин, А. Ю. Попов, Д. М. Ягудаев, Л. А. Фалалеева, И. Г. Русаков

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 48-55 ; Медицинский Совет; № 11 (2023); 48-55 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: метастатический рак, checkpoint inhibitors, maintenance immunotherapy, bladder cancer, urothelial carcinoma, metastatic cancer, ингибиторы контрольных точек, поддерживающая иммунотерапия, рак мочевого пузыря, уротелиальная карцинома

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7668/6802Test; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.). Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.; 2022. 252 с. Режим доступа: https://glavonco.ru/cancer_register/%D0%97%D0%98%D0%A1%202021%20%D1%8D%D0%BB.%20%D0%B2%D0%B5%D1%80%D1%81%D0%B8%D1%8F.pdfTest.; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551Test.; Теплов А.А., Грицкевич А.А., Степанова Ю.А., Мирошкина И.В., Пьяникин С.С., Дунаев С.А. и др. Первично-множественный рак переходно-клеточного эпителия: диагностика и особенности течения заболевания. Экспериментальная и клиническая урология. 2018;(4):22–28. Режим доступа: https://ecuro.ru/en/article/primary-multiple-cancer-transitionalepithelium-diagnostics-and-peculiarities-diseaseTest.; Гладков О.А., Зуков Р.А., Матвеев В.Б., Митин Т. Носов Д.А., Попов А.М. Практические рекомендации по лекарственному лечению рака мочевого пузыря. Злокачественные опухоли. 2022;12(3s2-1):589–606. https://doi.org/10.18027/2224-5057-2022-12-3s2-589-606Test; Грицкевич А.А., Попов А.Ю., Русаков И.Г., Возный Э.К., Макаров В.А., Гриднев Д.И. и др. Вторая линия терапии метастатической уротелиальной карциномы. Клинический случай применения препарата винфлунин. Медицинский совет. 2022;16(9):95–103. https://doi.org/10.21518/2079-701X-2022-16-9-95-103Test.; Kacew A., Sweis R.F. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020;11:575258. https://doi.org/10.3389/fimmu.2020.575258Test.; von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17): 3068–3077. https://doi.org/10.1200/JCO.2000.18.17.3068Test.; Sotelo M., Alonso-Gordoa T., Gajate P., Gallardo E., Morales-Barrera R., Pérez-Gracia J.L. et al. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Clin Transl Oncol. 2021;23(4):882–891. https://doi.org/10.1007/s12094-020-02482-9Test.; Bamias A., Tzannis K., Harshman L.C., Crabb S.J., Wong Y.-N., Kumar Pal S. et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective international study of invasive/advanced cancer of the urothelium (RISC). Ann Oncol. 2018;29(2):361–369. https://doi.org/10.1093/annonc/mdx692Test.; Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12(3):211–214. https://doi.org/10.1016/S1470-2045Test(10)70275-8.; De Santis M., Bellmunt J., Mead G., Kerst J.M., Leahy M., Maroto P. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–199. https://doi.org/10.1200/JCO.2011.37.3571Test.; Loehrer P.J. Sr., Einhorn L.H., Elson P.J., Crawford E.D., Kuebler P., Tannock I. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066–1073. https://doi.org/10.1200/JCO.1992.10.7.1066Test.; Gómez De Liaño A., Duran I. The continuing role of chemotherapy in the management of advanced urothelial cancer. Ther Adv Urol. 2018;10(12):455–480. https://doi.org/10.1177/1756287218814100Test.; Грицкевич А.А., Байтман Т.П., Мишугин С.В., Попов А.Ю., Оганян В.А., Русаков И.Г., Костин А.А. Опыт применения атезолизумаба в первой линии терапии метастатической уротелиальной карциномы. Медицинский совет. 2022;16(22):58–64. https://doi.org/10.21518/2079-701X-2022-16-22-58-64Test.; Gartrell B.A., He T., Sharma J., Sonpavde G. Update of systemic immunotherapy for advanced urothelial carcinoma. Urol Oncol. 2017;35(12):678–686. https://doi.org/10.1016/j.urolonc.2017.09.021Test.; Balar A.V., Galsky M.D., Rosenberg J.E., Powles T., Petrylak D.P., Bellmunt J. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. https://doi.org/10.1016/S0140-6736Test(16)32455-2.; Balar A.V., Castellano D., O’Donnell P.H., Grivas P., Vuky J., Powles T. et al. Firstline pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492. https://doi.org/10.1016/S1470-2045Test(17)30616-2.; Powles T., Durán I., van der Heijden M.S., Loriot Y., Vogelzang N.J., De Giorgi U. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757. https://doi.org/10.1016/S0140-6736Test(17)33297-X.; Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. https://doi.org/10.1016/S0140-6736Test(16)00561-4.; Massard C., Gordon M.S., Sharma S., Rafii S., Wainberg Z.A., Luke J. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–3125. https://doi.org/10.1200/JCO.2016.67.9761Test.; Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, singlearm, phase 2 trial. Lancet Oncol. 2017;18(3):312–322. https://doi.org/10.1016/S1470-2045Test(17)30065-7.; Apolo A.B., Infante J.R., Balmanoukian A., Patel M.R., Wang D., Kelly K. et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35(19):2117–2124. https://doi.org/10.1200/JCO.2016.71.6795Test.; Fradet Y., Bellmunt J., Vaughn D.J., Lee J.L., Fong L., Vogelzang N.J. et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970–976. https://doi.org/10.1093/annonc/mdz127Test.; Powles T., Park S.H., Voog E., Caserta C., Valderrama B.P., Gurney H. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–1230. https://doi.org/10.1056/NEJMoa2002788Test.; Loriot Y., Necchi A., Park S.H., Garcia-Donas J., Huddart R., Burgess E. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–348. https://doi.org/10.1056/NEJMoa1817323Test.; Padua T.C., Moschini M., Martini A., Pederzoli F., Nocera L., Marandino L. et al. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review. Urol Oncol. 2022;40(10):413–423. https://doi.org/10.1016/j.urolonc.2022.07.006Test.; Hoffman-Censits J.H., Lombardo K.A., Parimi V., Kamanda S., Choi W., Hahn N.M. et al. Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol. 2021;29(8):619–625. https://doi.org/10.1097/PAI.0000000000000938Test.; Tagawa S.T., Balar A.V., Petrylak D.P., Kalebasty A.R., Loriot Y., Flechon A. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474–2485. https://doi.org/10.1200/JCO.20.03489Test.; Heery C.R., O’Sullivan-Coyne G., Madan R.A., Cordes L., Rajan A., Rauckhorst M. et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598. https://doi.org/10.1016/S1470-2045Test(17)30239-5.; Grenga I., Donahue R.N., Lepone L.M., Richards J., Schlom J. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunol. 2016;5(5):e83. https://doi.org/10.1038/cti.2016.27Test.; Boyerinas B., Jochems C., Fantini M., Heery C.R., Gulley J.L., Tsang K.Y., Schlom J. Antibody-dependent cellular cytotoxicity activity of a novel anti-pd-l1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–1157. https://doi.org/10.1158/2326-6066.CIR-15-0059Test.; Patel M.R., Ellerton J., Infante J.R., Agrawal M., Gordon M., Aljumaily R. et al. Avelumab in Metastatic Urothelial Carcinoma after Platinum Failure (JAVELIN Solid Tumor): Pooled Results from Two Expansion Cohorts of an Open-Label, Phase 1 Trial. Lancet Oncol. 2018;19(1):51–64. https://doi.org/10.1016/S1470-2045Test(17)30900-2.; Apolo A.B., Ellerton J.A., Infante J.R., Agrawal M., Gordon M.S., Aljumaily R. et al. Avelumab as Second-Line Therapy for Metastatic, Platinum-Treated Urothelial Carcinoma in the Phase Ib JAVELIN Solid Tumor Study: 2-Year Updated Efficacy and Safety Analysis. J Immunother Cancer. 2020;8(2):e001246. https://doi.org/10.1136/jitc-2020-001246Test.; Maiorano B.A., De Giorgi U., Ciardiello D., Schinzari G., Cisternino A., Tortora G., Maiello E. Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. Biomedicines. 2022;10(2):411. https://doi.org/10.3390/biomedicines10020411Test.; Powles T., Park S.H., Voog E., Caserta C., Valderrama B.P., Gurney H. et al. Maintenance Avelumab + Best Supportive Care (BSC) versus BSC Alone after Platinum-Based First-Line (1L) Chemotherapy in Advanced Urothelial Carcinoma (UC): JAVELIN Bladder 100 Phase III Interim Analysis. J Clin Oncol. 2020;38:LBA1. https://doi.org/10.1200/JCO.2020.38.18_suppl.LBA1Test.; https://www.med-sovet.pro/jour/article/view/7668Test

الإتاحة: https://doi.org/10.21518/ms2023-244Test
https://doi.org/10.3322/caac.21551Test
https://doi.org/10.18027/2224-5057-2022-12-3s2-589-606Test
https://doi.org/10.21518/2079-701X-2022-16-9-95-103Test
https://doi.org/10.3389/fimmu.2020.575258Test
https://doi.org/10.1200/JCO.2000.18.17.3068Test
https://doi.org/10.1007/s12094-020-02482-9Test
https://doi.org/10.1093/annonc/mdx692Test
https://doi.org/10.1016/S1470-2045Test(10)70275-8
https://doi.org/10.1200/JCO.2011.37.3571Test

المؤلفون: A. A. Gritskevich, D. M. Monakov, M. V. Epifanova, A. A. Kostin, T. P. Baytman, S. V. Khromova, M. A. A. Al-Vadzhikh, А. А. Грицкевич, Д. М. Монаков, М. В. Епифанова, А. А. Костин, Т. П. Байтман, С. В. Хромова, М. А. А. Аль-Ваджих

المصدر: Andrology and Genital Surgery; Том 24, № 4 (2023); 155-160 ; Андрология и генитальная хирургия; Том 24, № 4 (2023); 155-160 ; 2412-8902 ; 2070-9781

مصطلحات موضوعية: эндоскопия, external genitalia, urethra, foreign body, endoscopy, наружные половые органы, уретра, инородное тело

وصف الملف: application/pdf

العلاقة: https://agx.abvpress.ru/jour/article/view/716/561Test; Williams M., Jezior J. Management of combat-related urological trauma in the modern era. Nat Rev Urol 2013;10(9):504–12. DOI:10.1038/nrurol.2013.148; Serkin F.B., Soderdahl D.W., Hernandez J. et al. Combat urologic trauma in US military overseas contingency operations. J Trauma 2010;69(Suppl 1):S175–8. DOI:10.1097/TA.0b013e3181e45cd1; Goldman C., Shaw N., du Plessis D. et al. Gunshot wounds to the penis and scrotum: a narrative review of management in civilian and military settings. Transl Androl Urol 2021;10(6):2596–608. DOI:10.21037/tau-20-1175; Hudak S.J., Morey A.F., Rozanski T.A., Fox CW Jr. Battlefield urogenital injuries: changing patterns during the past century. Urology 2005;65(6):1041–6. DOI:10.1016/j.urology.2004.11.031; Vucković I., Tucak A., Gotovac J. et al. Croatian experience in the treatment of 629 urogenital war injuries. J Trauma 1995;39(4):733–6. DOI:10.1097/00005373-199510000-00023; Tucak A., Lukacević T., Kuvezdić H. et al. Urogenital wounds during the war in Croatia in 1991/1992. J Urol 1995;153(1):121–2. DOI:10.1097/00005392-199501000-00043; Al-Azzawi I.S., Koraitim M.M. Lower genitourinary trauma in modern warfare: the experience from civil violence in Iraq. Injury 2014;45(5):885–9. DOI:10.1016/j.injury.2014.01.005; Al-Azzawi I.S., Koraitim M.M. Urethral and penile war injuries: the experience from civil violence in Iraq. Arab J Urol 2014;12(2):149–54. DOI:10.1016/j.aju.2013.11.002; Phonsombat S., Master V.A., McAninch J.W. Penetrating external genital trauma: a 30-year single institution experience. J Urol 2008;180(1):192–5; discussion 195–6. DOI:10.1016/j.juro.2008.03.041; Golovko S., Gybalo R., Lurin I. et al. Penetrating gunshot wounds to the penis: a case report of combat patient injured in the war in Ukraine. Int J Emerg Med 2023;16(1):5. DOI:10.1186/s12245-023-00481-5; Cerwinka W.H., Block N.L. Civilian gunshot injuries of the penis: the Miami experience. Urology 2009;73(4):877–80. DOI:10.1016/j.urology.2008.10.057; Kunkle D.A., Lebed B.D., Mydlo J.H., Pontari M.A. Evaluation and management of gunshot wounds of the penis: 20-year experience at an urban trauma center. J Trauma 2008;64(4):1038–42. DOI:10.1097/TA.0b013e3180342036; Balzano F.L., Hudak S.J. Military genitourinary injuries: past, present, and future. Transl Androl Urol 2018;7(4):646–52. DOI:10.21037/tau.2018.04.05; Шанава Г.Ш., Мосоян М.С., Грабский А.М., Арзуманян К.Г. Особенности извлечения инородных тел из нижних мочевыводящих путей. Урологические ведомости 2021;11(3):213–8. DOI:10.17816/uroved72148; https://agx.abvpress.ru/jour/article/view/716Test

الإتاحة: https://doi.org/10.17650/2070-9781-2023-24-4-155-160Test
https://doi.org/10.1038/nrurol.2013.148Test
https://doi.org/10.1097/TA.0b013e3181e45cd1Test
https://doi.org/10.21037/tau-20-1175Test
https://doi.org/10.1016/j.urology.2004.11.031Test
https://doi.org/10.1097/00005373-199510000-00023Test
https://doi.org/10.1097/00005392-199501000-00043Test
https://doi.org/10.1016/j.injury.2014.01.005Test
https://doi.org/10.1016/j.aju.2013.11.002Test
https://doi.org/10.1016/j.juro.2008.03.041Test

المؤلفون: M. V. Epifanova, A. A. Kostin, E. V. Gameeva, A. A. Gritskevich, S. A. Artemenko, A. A. Epifanov, М. В. Епифанова, А. А. Костин, Е. В. Гамеева, А. А. Грицкевич, C. А. Артеменко, А. А. Епифанов

المصدر: Andrology and Genital Surgery; Том 24, № 2 (2023); 41-48 ; Андрология и генитальная хирургия; Том 24, № 2 (2023); 41-48 ; 2412-8902 ; 2070-9781

مصطلحات موضوعية: экстракорпоральная ударно-волновая терапия, erectile dysfunction, rehabilitation, radical prostatectomy, platelet rich plasma, extracorporeal shock wave therapy, эректильная дисфункция, реабилитация, радикальная простатэктомия, аутоплазма, обогащенная тромбоцитарными факторами роста

وصف الملف: application/pdf

العلاقة: https://agx.abvpress.ru/jour/article/view/659/519Test; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209– 49. DOI:10.3322/caac.21660; Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021:71(1):7–33. DOI:10.3322/caac.21654; Simone G. The epidemiology of prostate cancer. In: Prostate Cancer. Ed. by S.R.J. Bott, K.L. Ng. Australia, Brisbane: Exon Publications, 2021. 158 p.; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.; EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022.; Haahr M.K., Jensen C.H., Toyserkani N.M. et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine 2016;5:204–10. DOI:10.1016/j.ebiom.2016.01.024; Huri M., Akel B.S., Sahin S. Rehabilitation of patients with prostate cancer. In: Prostate cancer – leading-edge diagnostic procedures and treatments. Ed. by R. Mohan. London: IntechOpen, 2016. Pp. 227–248. DOI:10.5772/63989; Ladegaard P.B.J., Mortensen J., Skov-Jeppesen S.M., Lund L. Erectile dysfunction a prospective randomized placebo-controlled study evaluating the effect of low-intensity extracorporeal shockwave therapy (LI-ESWT) in men with erectile dysfunction following radical prostatectomy. Sex Med 2021;9(3):100338. DOI:10.1016/j.esxm.2021.100338; Avulova S., Zhao Z., Lee D. et al. The effect of nerve sparing status on sexual and urinary function: 3-year results from the CEASAR study. J Urol 2018;199(5):1202–9. DOI:10.1016/j.juro.2017.12.037; Ko Y.H., Coelho R.F., Sivaraman A. et al. Retrograde versus antegrade nerve sparing during robot-assisted radical prostatectomy: which is better for achieving early functional recovery? Eur Urol 2013;63(1):169–77. DOI:10.1016/j.eururo.2012.09.051; Alemozaffar M., Duclos A., Hevelone N.D. et al. Technical refinement and learning curve for attenuating neurapraxia during robotic-assisted radical prostatectomy to improve sexual function. Eur Urol 2012;61(6):1222–8. DOI:10.1016/j.eururo.2012.02.053; Шпоть Е.В., Чиненов Д.В., Чернов Я.Н. и др. Сравнительные результаты нервосберегающей робот-ассистированной простатэктомии. Андрология и генитальная хирургия 2021;22(3):44–8. DOI:10.17650/1726-9784-2021-22-3-44-48.; Emanu J.C., Avildsen I.K., Nelson C.J. Erectile dysfunction after radical prostatectomy: prevalence, medical treatments, and psychosocial interventions. Curr Opin Support Palliat Care 2016;10(1):102–7. DOI:10.1097/SPC.0000000000000195; Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 2005;6(11):889–98. DOI:10.1038/nrn1788; Whalen M. Preventing erectile dysfunction after radical prostatectomy: nerve-sparing techniques, penile rehabilitation, and novel regenerative therapies. In: Prostatectomy. Ed. by T. Genadiev. London: IntechOpen, 2019. Pp. 129–174.; Bratu O., Oprea I., Marcu D. et al. Erectile dysfunction postradical prostatectomy – a challenge for both patient and physician. J Med Life 2017;10(1):13–18. PMID: 28255370.; Wang L., Sanford M.T., Xin Z. et al. Role of Schwann cells in the regeneration of penile and peripheral nerves. Asian J Androl 2015;17(5):776–82. DOI:10.4103/1008-682X.154306; Lagoda G., Sezen S.F., Burnett A.L. FK506 and rapamycin neuroprotect erection and involve different immunophilins in a rat model of cavernous nerve injury. J Sex Med 2009;6(7):1914–23. DOI:10.1111/j.1743-6109.2009.01293.x; Leungwattanakij S., Bivalacqua T.J., Usta M.F. et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003;24(2):239–45. DOI:10.1002/j.1939-4640.2003.tb02668.x; Cui Y., Liu X., Shi L., Gao Z. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Andrologia 2016;48(1):20–8. DOI:10.1111/and.12405; Hamilton Z., Mirza M. Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective. Res Rep Urol 2014;6:35–41. DOI:10.2147/RRU.S39560; Hebert K.J., Kohler T.S. Glans ischemia following inflatable penile prosthesis surgery. Transl Androl Urol 2020;9(2):824–7. DOI:10.21037/tau.2020.01.04; Lokeshwar S.D., Patel P., Shah S.M., Ramasamy R. A systematic review of human trials using stem cell therapy for erectile dysfunction. Sex Med Rev 2020;8(1):122–30. DOI:10.1016/j.sxmr.2019.08.003; Epifanova M.V., Gvasalia B.R., Durashov M.A., Artemenko S.A. Platelet-rich plasma therapy for male sexual dysfunction: myth or reality? Sex Med Rev 2020;8(1):106–13. DOI:10.1016/j.sxmr.2019.02.002; EAU Guidelines. Edn. presented at the EAU Annual Congress Milan, 2021.; Yao H., Wang X., Liu H. et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of lowintensity extracorporeal shock wave therapy in treating erectile dysfunction. Am J Mens Health 2022;16(2):15579883221087532. DOI:10.1177/15579883221087532; Епифанова М.В. Применение аутоплазмы, обогащенной тромбоцитарными факторами роста, в лечении эректильной дисфункции. Дис. … канд. мед. наук. М., 2016. 167 с.; Епифанова М.В. Применение технологий регенеративной медицины при сексуальной дисфункции и нарушении фертильности у мужчин. Дис. … д-ра. мед. наук. М., 2022. 400 с.; Lee J.W., Kwon O.H., Kim T.K. et al. Platelet-rich plasma: quantitative assessment of growth factor levels and comparative analysis of activated and inactivated groups. Arch Plast Surg 2013;40(5):530–5. DOI:10.5999/aps.2013.40.5.530; Nishio H., Saita Y., Kobayashi Y. et al. Platelet-rich plasma promotes recruitment of macrophages in the process of tendon healing. Regen Ther 2020;14:262–70. DOI:10.1016/j.reth.2020.03.009; Wang Z., Mudalal M., Sun Y. et al. The effects of leukocyte-platelet rich fibrin (L-PRF) on suppression of the expressions of the proinflammatory cytokines, and proliferation of Schwann cell, and neurotrophic factors. Sci Rep 2020;10(1):2421. DOI:10.1038/s41598-020-59319-2; Pereira C.T., Paxton Z.J., Li A.I. Involvement of PDGF-BB and IGF-1 in activation of human Schwann cells by platelet-rich plasma. Plast Reconstr Surg 2020;146(6):825e–7e. DOI:10.1097/PRS.0000000000007406; Zheng C., Zhu Q., Liu X. et al. Effect of platelet-rich plasma (PRP) concentration on proliferation, neurotrophic function and migration of Schwann cells in vitro. J Tissue Eng Regen Med 2016;10(5):428–36. DOI:10.1002/term.1756; Pelletier J., Roudier E., Abraham P. et al. VEGF-A promotes both pro-angiogenic and neurotrophic capacities for nerve recovery after compressive neuropathy in rats. Mol Neurobiol 2015;51(1):240–51. DOI:10.1007/s12035-014-8754-1; Hatanaka K., Ito K., Shindo T. et al. Molecular mechanisms of the angiogenic effects of low-energy shock wave therapy: roles of mechanotransduction. Am J Physiol Cell Physiol 2016;311(3):C378–85. DOI:10.1152/ajpcell.00152.2016; Pan M.M., Raees A., Kovac J.R. Low-intensity extracorporeal shock wave as a novel treatment for erectile dysfunction. Am J Mens Health 2016;10(2):146–8. DOI:10.1177/1557988315574511; Yahata K., Kanno H., Ozawa H. et al. Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury. J Neurosurg Spine 2016;25(6):745–5. DOI:10.3171/2016.4.SPINE15923; Jeong H.C., Bae W.J., Zhu G.Q. et al. Synergistic effects of extracorporeal shockwave therapy and modified Ojayeonjonghwan on erectile dysfunction in an animal model of diabetes. Investig Clin Urol 2019;60(4):285–94. DOI:10.4111/icu.2019.60.4.285; Jeon S.H., Shrestha K.R., Kim R.Y. et al. Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of post-prostatectomy erectile dysfunction. Urology 2016;88:226.e1–9. DOI:10.1016/j.urology.2015.10.021; Lin G., Reed-Maldonado A.B., Wang B. et al. In situ activation of penile progenitor cells with low-intensity extracorporeal shockwave therapy. J Sex Med 2017;14(4):493–501. DOI:10.1016/j.jsxm.2017.02.004; Patel A.N., Selzman C.H., Kumpati G.S. et al. Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients. J Cardiothorac Surg 2016;11(1):62. DOI:10.1186/s13019-016-0452-9; Gentile P., Di Pasquali C., Bocchini I. et al. Breast reconstruction with autologous fat graft mixed with platelet-rich plasma. Surg Innov 2013;20(4):370–6. DOI:10.1177/1553350612458544; Spartalis E.D., Tomos P., Dimitroulis D., Kouraklis G. Platelet-rich plasma in surgical oncology. Surg Innov 2014;21(4):441. DOI:10.1177/1553350613520516; Spartalis E.D., Tomos P., Konofaos P. et al. Breast reconstruction with autologous fat graft; does platelet-rich plasma affect patient’s survival? Int J Clin Exp Med 2014;7(1):329–30. PMID: 24482728.; Guo X., Wu Y., Hathaway H.J., Hartley R.S. Microenvironmental control of the breast cancer cell cycle. Anat Rec (Hoboken) 2012;295(4):553–62. DOI:10.1002/ar.22417; Levva S., Kotoula V., Kostopoulos I. et al. Prognostic evaluation of epidermal growth factor receptor (EGFR) genotype and phenotype parameters in triple-negative breast cancers. Cancer Genomics Proteomics 2017;14(3):181–95. DOI:10.21873/cgp.20030; Spartalis E., Tsilimigras D.I., Charalampoudis P. et al. The “Yin and Yang” of platelet-rich plasma in breast reconstruction after mastectomy or lumpectomy for breast cancer. Anticancer Res 2017;37(12):6557–62. DOI:10.1016/j.gene.2019.04.025; Luzo A.C.M., Fávaro WJ, Seabra AB, Durán N. What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review. Heliyon 2020;6(3):e03660. DOI:10.1016/j.heliyon.2020.e03660; Eichler C., Baucks C., Üner J. et al. Platelet-rich plasma (PRP) in breast cancer patients: an application analysis of 163 sentinel lymph node biopsies. Biomed Res Int 2020;2020:3432987. DOI:10.1155/2020/3432987; Haahr M.K., Harken C., Toyserkani N.M. et al. A 12-month follow-up after a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. Urology 2018;121:203.e6–203.e13. DOI:10.1016/j.urology.2018.06.018; Ding X.G., Li S.W., Zheng X.M. et al. The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 2009;11(2):215–21. DOI:10.1038/aja.2008.37; Wu C.C., Wu Y.N., Ho H.O. et al. The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model. J Sex Med 2012;9(11):2838–48. DOI:10.1111/j.1743-6109.2012.02881.x; Wu Y.N., Wu C.C., Sheu M.T. et al. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med 2016;10(10):E294–E304. DOI:10.1002/term.1806; Wu Y.N., Liao C.H., Chen K.C., Chiang H.S. Dual effect of chitosan activated platelet rich plasma (cPRP) improved erectile function after cavernous nerve injury. J Formos Med Assoc 2022;121(1 Pt 1):14–24. DOI:10.1016/j.jfma.2021.01.019; Gettman M. A Study evaluating intraoperative application of platelet-rich plasma to the neurovascular bundles during nervesparing radical prostatectomy: initial technical description and prospective early postoperative outcomes analysis. Available at: https://clinicaltrials.gov/ct2/show/NCT02957149Test; Porst H. Review of the current status of low intensity extracorporeal shockwave therapy (Li-ESWT) in erectile dysfunction (ED), Peyronie’s disease (PD), and sexual rehabilitation after radical prostatectomy with special focus on technical aspects of the different marketed ESWT devices including personal experiences in 350 patients. Sex Med Rev 2021;9(1):93–122. DOI:10.1016/j.sxmr.2020.01.006; Frey A., Sønksen J., Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol 2016;50(2):123–7. DOI:10.3109/21681805.2015.1100675; Zewin T.S., El-Assmy A., Harraz A.M. et al. Efficacy and safety of low-intensity shock wave therapy in penile rehabilitation post nerve-sparing radical cystoprostatectomy: a randomized controlled trial. Int Urol Nephrol 2018;50(11):2007–14. DOI:10.1007/s11255-018-1987-6; Baccaglini W., Pazeto C.L., Corrêa Barros E.A. et al. The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med 2020;17(4):688–94. DOI:10.1016/j.jsxm.2019.12.024; Епифанова М.В., Каприн А.Д., Костин А.А. и др. Способ лечения эректильной дисфункции у пациентов, перенесших радикальную простатэктомию или брахитерапию. Патент на изобретение RU 2 741 204 C2, 22.01.2021. Бюлл. № 16 от 04.06.2020.; https://agx.abvpress.ru/jour/article/view/659Test

الإتاحة: https://doi.org/10.17650/2070-9781-2023-24-2-41-48Test
https://doi.org/10.3322/caac.21660Test
https://doi.org/10.3322/caac.21654Test
https://doi.org/10.1016/j.ebiom.2016.01.024Test
https://doi.org/10.5772/63989Test
https://doi.org/10.1016/j.esxm.2021.100338Test
https://doi.org/10.1016/j.juro.2017.12.037Test
https://doi.org/10.1016/j.eururo.2012.02.053Test
https://doi.org/10.17650/1726-9784-2021-22-3-44-48Test
https://doi.org/10.1097/SPC.0000000000000195Test

المؤلفون: A. Mansur, A. A. Gritskievich, A. A. Kostin, N. G. Kulchenko, O. M. Pospelova, G. E. Kalinycheva, А. Мансур, А. А. Грицкевич, А. А. Костин, Н. Г. Кульченко, О. М. Поспелова, Г. Е. Калинычева

المصدر: Andrology and Genital Surgery; Том 23, № 4 (2022); 74-80 ; Андрология и генитальная хирургия; Том 23, № 4 (2022); 74-80 ; 2412-8902 ; 2070-9781

مصطلحات موضوعية: интенсивность боли, quality of life, health status assessment questionnaire SF-36, mental health, bodily pain, качество жизни, опросник оценки качества здоровья SF-36, психологическое здоровье

وصف الملف: application/pdf

العلاقة: https://agx.abvpress.ru/jour/article/view/618/490Test; Prasad S.R., Menias C.O., Narra V.R. et al. Cross-sectional imaging of the female urethra: technique and results. Radiographics 2005;25(3):749–61. DOI:10.1148/rg.253045067; Eilber K.S., Raz S. Benign cystic lesions of the vagina: a literature review. J Urol 2003;170(3):717–22. DOI:10.1097/01.ju.0000062543.99821.a2; Sharifiaghdas F., Daneshpajooh A., Mirzaei M. Paraurethral cyst in adult women: experience with 85 cases. Urol J 2014;11(5):1896– 9. DOI:10.22037/uj.v11i05.2018; Köse O., Aydemir H., Metin O. et al. Experiences with the management of paraurethral cysts in adult women. Cent European J Urol 2013;66(4):477–80. DOI:10.5173/ceju.2013.04.art24; Noorwali F., Alboloshi E. Paraurethral cyst with multiple stones: a case report. Urol Case Rep 2021;39:101774. DOI:10.1016/j.eucr.2021.101774; Костин А.А., Шаплыгин Л.В., Кульченко Н.Г., Мансур А. Комбинированное лечение инфицированной кисты парауретральной железы. Исследования и практика в медицине 2021;8(1):69–74. DOI:10.17709/2409-2231-2021-8-1-7; Saito J., Tanaka H., Hoshina M. et al. Paraurethral cyst in a female newborn: a case report. Pediatr Int 2020;62(1):103–5. DOI:10.1111/ped.14043; Yonguc T., Bozkurt I.H., Polat S. et al. Surgical management of female paraurethral cyst with concomitant stress urinary incontinence. Int Braz J Urol 2017;43(6):1194. DOI:10.1590/S1677-5538.IBJU.2014.0582; Филимонов В.Б., Васин Р.В., Панченко В.Н. Особенности консервативной терапии доброкачественной гиперплазии предстательной железы у пациентов с метаболическим синдромом: лечение до достижения цели («Treat to Target»). Исследования и практика в медицине 2020;7(4):94–104. DOI:10.17709/2409-2231-2020-7-4-8; Fumincelli L., Mazzo A., Martins J.C.A., Mendes I.A.C. Quality of life and ethics: a concept analysis. Nurs Ethics 2019;26(1):61–70. DOI:10.1177/0969733016689815; Gilbert S.M. Quality of life and urinary diversion. Urol Clin North Am 2018;45(1):101–11. DOI:10.1016/j.ucl.2017.09.011; Kumar K., Robertson D. Superficial dyspareunia. CMAJ 2017;189(24):E836. DOI:10.1503/cmaj.161337; Busto Martín L., Barguti I., Andraca A.Z. et al. [Cyst of the skene’s gland: report of four cases and bibliographic review (in English, Spanish)]. Arch Esp Urol 2010;63(3):238–42.; Пушкарь Д.Ю., Анисимов А.В. Дифференциальная диагностика и лечение парауретральной кисты и/или дивертикула уретры. Урология 2007;4:49–54.; Foster J., Lemack G., Zimmern P. Skene’s gland cyst excision. Int Urogynecol J 2016;27(5):817–20. DOI:10.1007/s00192-015-2872-9; Gross E., Brubaker L. Dyspareunia in цomen. JAMA 2022;327(18):1817–8. DOI:10.1001/jama.2022.4853; Giovannetti O., Tomalty D., Gaudet D. et. al. Immunohistochemical investigation of autonomic and sensory innervation of anterior vaginal wall female periurethral tissue: a study of the surgical field of mid-urethral sling surgery using cadaveric simulation. J Sex Med 2021;18(7):1167–80. DOI:10.1016/j.jsxm.2021.05.002; Tomalty D., Giovannetti O., Hannan J. et. al. Should we call it a prostate? A review of the female periurethral glandular tissue morphology, histochemistry, nomenclature, and role in iatrogenic sexual dysfunction. Sex Med Rev 2022;10(2):183–94. DOI:10.1016/j.sxmr.2021.12.002; https://agx.abvpress.ru/jour/article/view/618Test

الإتاحة: https://doi.org/10.17650/2070-9781-2022-23-4-74-80Test
https://doi.org/10.1148/rg.253045067Test
https://doi.org/10.1097/01.ju.0000062543.99821.a2Test
https://doi.org/10.22037/uj.v11i05.2018Test
https://doi.org/10.5173/ceju.2013.04.art24Test
https://doi.org/10.1016/j.eucr.2021.101774Test
https://doi.org/10.17709/2409-2231-2021-8-1-7Test
https://doi.org/10.1111/ped.14043Test
https://doi.org/10.1590/S1677-5538.IBJU.2014.0582Test
https://doi.org/10.17709/2409-2231-2020-7-4-8Test

المؤلفون: A. A. Gritskevich, Ya. D. Prokhorova, T. P. Baitman, E. Yu. Gritskevich, A. A. Kostin, А. А. Грицкевич, Я. Д. Прохорова, Т. П. Байтман, Е. Ю. Грицкевич, А. А. Костин

المصدر: Research and Practical Medicine Journal; Том 9, № 2 (2022); 143-155 ; Research'n Practical Medicine Journal; Том 9, № 2 (2022); 143-155 ; 2410-1893 ; 2409-2231 ; 10.17709/2410-1893-2022-9-2

مصطلحات موضوعية: андрогендепривационная терапия, prostate cancer, androgens, testosterone, androgen deprivation therapy, рак предстательной железы, андрогены, тестостерон

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/813/491Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/813/651Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/813/652Test; Малинникова Е. Ю. Новая коронавирусная инфекция. Сегодняшний взгляд на пандемию XXI века. Инфекционные болезни: новости, мнения, обучение. 2020;9(2):18–32. https://doi.org/10.33029/2305Test‑3496‑2020‑9‑2‑18‑32; Seymen CM. The other side of COVID‑19 pandemic: Effects on male fertility. J Med Virol. 2021 Mar;93(3):1396–1402. https://doi.org/10.1002/jmv.26667Test; World Health Organization (WHO). WHO Coronavirus (COVID‑19) Dashboard [Internet]. WHO; 2021. Доступно по: https://covid19.who.intTest/, Дата обращения: 25.04.2022.; Беляев А. М., Носов А. К., Игнатова О. К., Байрамов Х. Н., Рябинин Р. И., Щекутеев Н. А., и др. Метаморфозы онкоурологии после первой волны пандемии COVID‑19. Экспериментальная и клиническая урология. 2020;(3):16–24. https://doi.org/10.29188/2222Test‑8543‑2020‑12‑3‑16‑24; Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID‑19: a review of the putative role of sex hormones and X chromosome. J Endocrinol Invest. 2021 May;44(5):951–956. https://doi.org/10.1007/s40618Test‑020‑01383‑6; Каприн А. Д., Гамеева Е. В., Поляков А. А., Корниецкая А. Л., Рубцова Н. А., Феденко А. А. Влияние пандемии COVID‑19 на онкологическую практику. Сибирский онкологический журнал. 2020;19(3):5–22. https://doi.org/10.21294/1814Test‑4861‑2020‑19‑3‑5‑22; Zhou P P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270–273. https://doi.org/10.1038/s41586Test‑020‑2012‑7; Hoffmann M, Kleine‑Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS‑CoV‑2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271–280. https://doi.org/10.1016/j.cell.2020.02.052Test; Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS‑CoV‑2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020 May 18;39(10):e105114. https://doi.org/10.15252/embj.20105114Test; Rahman N, Basharat Z, Yousuf M, Castaldo G, Rastrelli L, Khan H. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS‑CoV‑2). Molecules. 2020 May 12;25(10):2271. https://doi.org/10.3390/molecules25102271Test; Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen‑deprivation therapies for prostate cancer and risk of infection by SARS‑CoV‑2: a population‑based study (N = 4532). Ann Oncol. 2020 Aug;31(8):1040–1045. https://doi.org/10.1016/j.annonc.2020.04.479Test; Pinato DJ, Zambelli A, Aguilar‑Company J, Bower M, Sng C, Salazar R, et al. Clinical portrait of the SARS‑CoV‑2 epidemic in European cancer patients. Cancer Discov. 2020 Jul 31;10(10):1465–1474. https://doi.org/10.1158/2159Test‑8290.CD‑20‑0773; Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallome G, Boccardo F. Sex Hormones and Hormone Therapy during COVID‑19 Pandemic: Implications for Patients with Cancer. Cancers (Basel). 2020 Aug 18;12(8):2325. https://doi.org/10.3390/cancers12082325Test; Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID‑19 in the New York City Area. JAMA. 2020 May 26;323(20):2052–2059. https://doi.org/10.1001/jama.2020.6775Test; Onder G, Rezza G, Brusaferro S. Case‑Fatality Rate and Characteristics of Patients Dying in Relation to COVID‑19 in Italy. JAMA. 2020 May 12;323(18):1775–1776. https://doi.org/10.1001/jama.2020.4683Test; Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708–1720. https://doi.org/10.1056/NEJMoa2002032Test; Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS‑CoV‑2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574–1581. https://doi.org/10.1001/jama.2020.5394Test; Stall NM, Wu W, Lapointe‑Shaw L, Fisman DN, Giannakeas V, Hillmer MP, et al. Sex‑and Age‑Specific Differences in COVID‑19 Testing, Cases, and Outcomes: A Population‑Wide Study in Ontario, Canada. J Am Geriatr Soc. 2020 Oct;68(10):2188–2191. https://doi.org/10.1111/jgs.16761Test; Lochlainn MN, Lee KA, Sudre CH, Varsavsky T, Cardoso MJ, Menni C, et al. Key predictors of attending hospital with COVID19: An association study from the COVID Symptom Tracker App in 2,618,948 individuals. medRxiv. 2020 Jan 1;2020.04.25.20079251. https://doi.org/10.1101/2020.04.25.20079251Test; Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID‑19 outcomes. Nat Rev Immunol. 2020 Jul;20(7):442–447. https://doi.org/10.1038/s41577Test‑020‑0348‑8; Handelsman DJ, Hirschberg AL, Bermon S. Circulating Testosterone as the Hormonal Basis of Sex Differences in Athletic Performance. Endocr Rev. 2018 Oct 1;39(5):803–829. https://doi.org/10.1210/er.2018Test‑00020; Grossmann M, Ng Tang Fui M, Cheung AS. Late‑onset hypogonadism: metabolic impact. Andrology. 2020 Nov;8(6):1519–1529. https://doi.org/10.1111/andr.12705Test; Assyov Y, Gateva A, Karamfilova V, Gatev T, Nedeva I, Velikova T, et al. Impact of testosterone treatment on circulating irisin in men with late‑onset hypogonadism and metabolic syndrome. Aging Male. 2020 Dec;23(5):1381–1387. https://doi.org/10.1080/13685538.2020.1770721Test; Schroeder M, Schaumburg B, Müller Z, Parplys A, Jarczak D, Nierhaus A, et al. Sex hormone and metabolic dysregulations are associated with critical illness in male Covid‑19 patients. medRxiv. 2020 Jan 1;2020.05.07.20073817. https://doi.org/10.1101/2020.05.07.20073817Test; Shen LW, Qian MQ, Yu K, Narva S, Yu F, Wu YL, et al. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G‑quadruplex and hence down‑regulating TMPRSS2 expression. Sci Rep. 2020 May 6;10(1):7635. https://doi.org/10.1038/s41598Test‑020‑64368‑8; Piva F, Sabanovic B, Cecati M, Giulietti M. Expression and co‑expression analyses of TMPRSS2, a key element in COVID‑19. Eur J Clin Microbiol Infect Dis. 2021 Feb;40(2):451–455. https://doi.org/10.1007/s10096Test‑020‑04089‑y; Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS‑CoV‑2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‑19 risk factors. Allergy. 2020 Nov;75(11):2829–2845. https://doi.org/10.1111/all.14429Test; Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020 Jul;146(1):80–88.e8. https://doi.org/10.1016/j.jaci.2020.05.004Test; Tang L, Zhu Q, Wang Z, Shanahan CM, Bensen JT, Fontham ETH, et al. Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):990–999. https://doi.org/10.1158/1055Test‑9965.EPI‑20‑1389; Mohamad NV, Wong SK, Wan Hasan WN, Jolly JJ, Nur‑Farhana MF, Ima‑Nirwana S, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019 Jun;22(2):129–140. https://doi.org/10.1080/13685538.2018.1482487Test; Baldassarri M, Picchiotti N, Fava F, Fallerini C, Benetti E, Daga S, et al. Shorter androgen receptor polyQ alleles protect against life‑threatening COVID‑19 disease in European males. EBioMedicine. 2021 Mar;65:103246. https://doi.org/10.1016/j.ebiom.2021.103246Test; Демидова Т. Ю., Волкова Е. И., Грицкевич Е. Ю. Особенности течения и последствия COVID‑19 у пациентов с избыточным весом и ожирением. Уроки текущей пандемии. Ожирение и метаболизм. 2020;17(4):375–384. https://doi.org/10.14341/omet12663Test; Lapauw B, Kaufman JM. Management of Endocrine Disease: Rationale and current evidence for testosterone therapy in the management of obesity and its complications. Eur J Endocrinol. 2020 Dec;183(6):R167–R183. https://doi.org/10.1530/EJETest‑20‑0394; Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase‑4 (DPP4) inhibition in COVID‑19. Acta Diabetol. 2020 Jul;57(7):779–783. https://doi.org/10.1007/s00592Test‑020‑01539‑z; Tanezha V. Sex Hormones Determine Immune Response. Front Immunol. 2018;9:1931. https://doi.org/10.3389/fimmu.2018.01931Test; Reyes‑García J, Montaño LM, Carbajal‑García A, Wang YX. Sex Hormones and Lung Inflammation. Adv Exp Med Biol. 2021;1304:259–321. https://doi.org/10.1007/978Test‑3‑030‑68748‑9_15; Chanana N, Palmo T, Sharma K, Kumar R, Graham BB, Pasha Q. Sex‑derived attributes contributing to SARS‑CoV‑2 mortality. Am J Physiol Endocrinol Metab. 2020 Sep 1;319(3):E562–E567. https://doi.org/10.1152/ajpendo.00295.2020Test; Messina G, Polito R, Monda V, Cipolloni L, Di Nunno N, Di Mizio G, et al. Functional Role of Dietary Intervention to Improve the Outcome of COVID‑19: A Hypothesis of Work. Int J Mol Sci. 2020 Apr 28;21(9):3104. https://doi.org/10.3390/ijms21093104Test; Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID‑19 pneumonia. Cytokine Growth Factor Rev. 2020 Jun;53:38–42. https://doi.org/10.1016/j.cytogfr.2020.04.002Test; Papadopoulos V, Li L, Samplaski M. Why does COVID‑19 kill more elderly men than women? Is there a role for testosterone? Andrology. 2021 Jan;9(1):65–72. https://doi.org/10.1111/andr.12868Test; Van den Berg DF, Te Velde AA. Severe COVID‑19: NLRP3 Inflammasome Dysregulated. Front Immunol. 2020 Jun 26;11:1580. https://doi.org/10.3389/fimmu.2020.01580Test; Chen S, Markman JL, Shimada K, Crother TR, Lane M, Abolhesn A, et al. Sex‑Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor‑Deficient Mice. JACC Basic Transl Sci. 2020 Jun;5(6):582–598. https://doi.org/10.1016/j.jacbts.2020.03.016Test; Flaifel A, Guzzetta M, Occidental M, Najari BB, Melamed J, Thomas KM, et al. Testicular Changes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2). Arch Pathol Lab Med. 2021 Jan 1;145(1):8–9. https://doi.org/10.5858/arpa.2020Test‑0487‑LE; Duarte‑Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes‑Gouvêa MS, Dos Santos ABG, et al. Testicular pathology in fatal COVID‑19: A descriptive autopsy study. Andrology. 2022 Jan;10(1):13–23. https://doi.org/10.1111/andr.13073Test; Shi T, Dansen TB. Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both? Antioxid Redox Signal. 2020 Oct 20;33(12):839–859. https://doi.org/10.1089/ars.2020.8074Test; Grimes JM, Grimes KV. p38 MAPK inhibition: A promising therapeutic approach for COVID‑19. J Mol Cell Cardiol. 2020 Jul;144:63–65. https://doi.org/10.1016/j.yjmcc.2020.05.007Test; Jing J, Ding N, Wang D, Ge X, Ma J, Ma R, et al. Oxidized‑LDL inhibits testosterone biosynthesis by affecting mitochondrial function and the p38 MAPK/COX‑2 signaling pathway in Leydig cells. Cell Death Dis. 2020 Aug 14;11(8):626. https://doi.org/10.1038/s41419Test‑020‑02751‑z; Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghoshal AK, Erlich EC, et al. Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID‑19. JAMA Netw Open. 2021 May 3;4(5):e2111398. https://doi.org/10.1001/jamanetworkopen.2021.11398Test; Schroeder M, Schaumburg B, Mueller Z, Parplys A, Jarczak D, Roedl K, et al. High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID‑19 patients: a retrospective cohort study. Emerg Microbes Infect. 2021 Dec;10(1):1807–1818. https://doi.org/10.1080/22221751.2021.1969869Test; Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Randeva HS. Polycystic ovary syndrome (PCOS) and COVID‑19: an overlooked female patient population at potentially higher risk during the COVID‑19 pandemic. BMC Med. 2020 Jul 15;18(1):220. https://doi.org/10.1186/s12916Test‑020‑01697‑5; Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, et al. Low testosterone levels predict clinical adverse outcomes in SARS‑CoV‑2 pneumonia patients. Andrology. 2021 Jan;9(1):88–98. https://doi.org/10.1111/andr.12821Test; Cinislioglu AE, Cinislioglu N, Demirdogen SO, Sam E, Akkas F, Altay MS, et al. The relationship of serum testosterone levels with the clinical course and prognosis of COVID‑19 disease in male patients: A prospective study. Andrology. 2022 Jan;10(1):24–33. https://doi.org/10.1111/andr.13081Test; Ma L, Xie W, Li D, Shi L, Mao Y, Xiong Y, et al. Effect of SARS‑CoV‑2 infection upon male gonadal function: A single center‑based study. medRxiv. 2020 Jan 1;2020.03.21.20037267. https://doi.org/10.1101/2020.03.21.20037267Test; Datta S, Sengupta P. SARS‑CoV‑2 and Male Infertility: Possible Multifaceted Pathology. Reprod Sci. 2021 Jan;28(1):23–26. https://doi.org/10.1007/s43032Test‑020‑00261‑z; Rambhatla A, Bronkema CJ, Corsi N, Keeley J, Sood A, Affas Z, et al. COVID‑19 Infection in Men on Testosterone Replacement Therapy. J Sex Med. 2021 Jan;18(1):215–218. https://doi.org/10.1016/j.jsxm.2020.09.013Test; Bianchi VE. The Anti‑Inflammatory Effects of Testosterone. J Endocr Soc. 2019 Jan 1;3(1):91–107. https://doi.org/10.1210/js.2018Test‑00186; Aboudounya MM, Heads RJ. COVID‑19 and Toll‑Like Receptor 4 (TLR4): SARS‑CoV‑2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. Mediators Inflamm. 2021;2021:8874339. https://doi.org/10.1155/2021/8874339Test; Pozzilli P, Lenzi A. Commentary: Testosterone, a key hormone in the context of COVID‑19 pandemic. Metabolism. 2020 Jul;108:154252. https://doi.org/10.1016/j.metabol.2020.154252Test; Salonia A, Corona G, Giwercman A, Maggi M, Minhas S, Nappi RE, et al. SARS‑CoV‑2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. Andrology. 2021 Jan;9(1):19–22. https://doi.org/10.1111/andr.12811Test; Koskinen M, Carpen O, Honkanen V, Seppänen MRJ, Miettinen PJ, Tuominen JA, et al. Androgen deprivation and SARS‑CoV‑2 in men with prostate cancer. Ann Oncol. 2020 Oct;31(10):1417–1418. https://doi.org/10.1016/j.annonc.2020.06.015Test; https://www.rpmj.ru/rpmj/article/view/813Test

الإتاحة: https://doi.org/10.17709/2410-1893-2022-9-2-13Test
https://doi.org/10.17709/2410-1893-2022-9-2Test
https://doi.org/10.33029/2305Test‑3496‑2020‑9‑2‑18‑32
https://doi.org/10.1002/jmv.26667Test
https://doi.org/10.29188/2222Test‑8543‑2020‑12‑3‑16‑24
https://doi.org/10.1007/s40618Test‑020‑01383‑6
https://doi.org/10.21294/1814Test‑4861‑2020‑19‑3‑5‑22
https://doi.org/10.1038/s41586Test‑020‑2012‑7
https://doi.org/10.1016/j.cell.2020.02.052Test
https://doi.org/10.15252/embj.20105114Test

المؤلفون: Yu. A. Stepanova, O. I. Zhavoronkova, Ya. Ya. Gavrilov, O. A. Chekhoeva, A. A. Gritskevich, A. V. Glotov, Ю. А. Степанова, О. И. Жаворонкова, Я. Я. Гаврилов, О. А. Чехоева, А. А. Грицкевич, А. В. Глотов

المصدر: Medical Visualization; Том 27, № 1 (2023); 99-119 ; Медицинская визуализация; Том 27, № 1 (2023); 99-119 ; 2408-9516 ; 1607-0763

مصطلحات موضوعية: рецидив, multiple primary kidney cancer, radiofrequency ablation, dynamic monitoring, recurrence, первично-множественный рак почки, радиочастотная абляция, динамический мониторинг

وصف الملف: application/pdf

العلاقة: https://medvis.vidar.ru/jour/article/view/1309/779Test; Клиническая онкоурология / Под ред. Б.П. Матвеева. М.: Вердана, 2011. 934 с.; Wong M.C.S., Goggins W.B., Yip B.H.K. et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci. Rep. 2017; 7 (1): 15698. http://doi.org/10.1038/s41598-017-15922-4Test.; Mahdavifar N., Mohammadian M., Ghoncheh M., Salehiniya H. Incidence, mortality and risk factors of kidney cancer in the world. WCRJ. 2018; 5 (1): e1013. http://doi.org/10.32113/wcrj_20183_1013Test; Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология. 2019; 5 (2): 15–24. http://doi.org/10.17650/1726-9776-2019-15-2-15-24Test; Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021; 71 (3): 209–249. http://doi.org/10.3322/caac.21660Test; Escudier B., Porta C., Schmidinger M. et al.; ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019; 30 (5): 706–720. http://doi.org/10.1093/annonc/mdz056Test; Kümmerlin I.P., ten Kate F.J., Wijkstra H. et al. Changes in the stage and surgical management of renal tumours during 1995-2005: an analysis of the Dutch national histopathology registry. BJU Int. 2008; 102 (8): 946–951. http://doi.org/10.1111/j.1464-410X.2008.07770.xTest; Nguyen M.M., Gill I.S., Ellison L.M. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J. Urol. 2006; 176 (6, Pt 1): 2397–2400. http://doi.org/10.1016/j.juro.2006.07.144Test; Gervais D.A., McGovern F.J., Arellano R.S., McDougal W.S., Mueller P.R. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. Am. J. Roentgenol. 2005; 185 (1): 64–71. http://doi.org/10.2214/ajr.185.1.01850064Test; Gervais D.A., Arellano R.S., McGovern F.J. et al. Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors. Am. J. Roentgenol. 2005; 185 (1): 72–80. http://doi.org/10.2214/ajr.185.1.01850072Test; Павлов А.Ю., Клименко А.А., Момджан Б.К., Иванов С.А. Радиочастотная интерстициальная термоабляция (РЧА) рака почки. Онкоурология. 2011; 2–3: 112–113.; Wendler J.J., Porsch M., Nitschke S. et al. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial). Contemp. Clin. Trials. 2015; 43: 10–19. http://doi.org/10.1016/j.cct.2015.05.002Test; Atwell T.D., Vlaminck J.J., Boorjian S.A. et al. Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. J. Vasc. Interv. Radiol. 2015; 26 (6): 792–729. http://doi.org/10.1016/j.jvir.2015.02.010Test; Yu J., Zhang X., Liu H. et al. Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients. Radiology. 2020; 294 (3): 698–706. http://doi.org/10.1148/radiol.2020190919Test; Zlotta A.R., Wildschutz T., Raviv G. et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J. Endourol. 1997; 11 (4): 251–258. http://doi.org/10.1089/end.1997.11.251Test; Goldberg S.N., Gazelle G.S., Mueller P.R. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am. J. Roentgenol. 2000; 174: 323–331. http://doi.org/10.2214/ajr.174.2.1740323Test; Goldberg S.N., Dupuy D.E. Image-guided radiofrequency tumor ablation: challenges and opportunities: part I. J. Vasc. Interv. Radiol. 2001; 12: 1021–1032.; Yang Y., Chen S., Chen F. et al. Outcome of radiofrequency ablation over partial nephrectomy for small renal mass (; Matsumoto E.D., Johnson D.B., Ogan K. et al. Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors. Urology. 2005; 65 (5): 877–881. http://doi.org/10.1016/j.urology.2004.12.011Test; Park S., Anderson J.K., Matsumoto E.D. et al. Radio-frequency ablation of renal tumors: intermediate-term results. J. Endourol. 2006; 20 (8): 569–573. http://doi.org/10.1089/end.2006.20.569Test; Hegarty N.J., Gill I.S., Desai M.M. et al. Probe-ablative nephron-sparing surgery: cryoablation versus radio-frequency ablation. Urology. 2006; 68 (1, Suppl.): 7–13. http://doi.org/10.1016/j.urology.2005.12.049Test; Zagoria R.J., Traver M.A., Werle D.M. et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. Am. J. Roentgenol. 2007; 189 (2): 429–436. http://doi.org/10.2214/AJR.07.2258Test; Kim J.H., Kim T.H., Kim S.D. et al. Radiofrequency ablation of renal tumors: our experience. Korean J. Urol. 2011; 52 (8): 531–537. http://doi.org/10.4111/kju.2011.52.8.531Test; Lorber G., Glamore M., Doshi M. et al. Long-term oncologic outcomes following radiofrequency ablation with real-time temperature monitoring for T1a renal cell cancer. Urol. Oncol. 2014; 32 (7): 1017–1023. http://doi.org/10.1016/j.urolonc.2014.03.005Test; Lay A.H., Faddegon S., Olweny E.O. et al. Oncologic Efficacy of Radio Frequency Ablation for Small Renal Masses: Clear Cell vs Papillary Subtype. J. Urol. 2015; 194 (3): 653–657. http://doi.org/10.1016/j.juro.2015.03.115Test; Калпинский А.С., Алексеев Б.Я., Каприн А.Д., Воробьев Н.В., Нюшко К.М., Канукоев К.Ю., Вокач Д.С. Роль чрескожной радиочастотной абляции в лечении опухолей почек. Тюменский медицинский журнал. 2015; 17 (1): 39–44.; Siekiera J., Jasinski M., Mikołajczak W. Radiofrequency ablation of small renal masses in comorbid patients. Wideochir. Inne Tech. Maloinwazyjne. 2018; 13 (2): 212–214. http://doi.org/10.5114/wiitm.2018.74462Test; Johnson B.A., Sorokin I., Cadeddu J.A. Ten-Year Out-comes of Renal Tumor Radio Frequency Ablation. J. Urol. 2019; 201 (2): 251–258. http://doi.org/10.1016/j.juro.2018.08.045Test; Долгушин Б.И., Косырев Ю.В., Рампрабанант С. Радиочастотная аблация в онкологии. Практическая онкология. 2007; 8 (4): 219–227.; Salagierski M., Salagierski M.S. Radiofrequency ablation: a minimally invasive approach in kidney tumor management. Cancers (Basel). 2010; 2 (4): 1895–1900. http://doi.org/10.3390/cancers2041895Test; Gervais D.A., McGovern F.J., Arellano R.S. et al. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003; 226: 417–424. http://doi.org/10.1148/radiol.2262012062Test; Farrell M.A., Charboneau J.W., Callstrom M.R. et al. Paranephric water instillation: a technique to prevent bowel injury during percutaneous renal radiofrequency ablation. Am. J. Roentgenol. 2003; 181 (5): 1315–1317. http://doi.org/10.2214/ajr.181.5.1811315Test; Kurup A.N. Percutaneous Ablation for Small Renal Masses – Complications. Semin. Intervent. Radiol. 2014; 31 (1): 42–49. http://doi.org/10.1055/s-0033-1363842Test; Meloni M.F., Goldberg S.N., Livraghi T. et al. Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. Am. J. Roentgenol. 2001; 177 (2): 375–380. http://doi.org/10.2214/ajr.177.2.1770375Test; Wah T.M., Irving H.C., Gregory W. et al. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int. 2014; 113 (3): 416–428. http://doi.org/10.1111/bju.12349Test; Kong W.T., Zhang W.W., Guo H.Q. et al. Application of contrast-enhanced ultrasonography after radiofrequency ablation for renal cell carcinoma: is it sufficient for assessment of therapeutic response? Abdom. Imaging. 2011; 36 (3): 342–347. http://doi.org/10.1007/s00261-010-9665-xTest; Allard C.B., Coret A., Dason S. et al. Contrast-enhanced Ultrasonography for Surveillance of Radiofrequency-ablated Renal Tumors: A Prospective, Radiologist-blinded Pilot Study. Urology. 2015; 86 (6): 1174–1178. http://doi.org/10.1016/j.urology.2015.04.062Test; Ito K., Soga S., Seguchi K. et al. Clinical outcomes of percutaneous radiofrequency ablation for small renal cancer. Oncol. Lett. 2017; 14 (1): 918–924. http://doi.org/10.3892/ol.2017.6262Test; Ogan K., Jacomides L., Dolmatch B.L. et al. Percutaneous radiofrequency ablation of renal tumors: technique, limitations, and morbidity. Urology. 2002; 60 (6): 954–895. http://doi.org/10.1016/s0090-4295Test(02)02096-4; Rane A., Stein R., Cadeddu J. Focal therapy for renal mass lesions: where do we stand in 2012? BJU Int. 2012; 109 (4): 491–492. http://doi.org/10.1111/j.1464-410X.2011.10855.xTest; Livraghi T., Goldberg S.N., Lazzaroni S. et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000; 214 (3): 761–768. http://doi.org/10.1148/radiology.214.3.r00mr02761Test; Cholley I., Correas J.M., Masson-Lecomte A. et al. Comparaison des résultats opératoires et oncologiques de la néphrectomie partielle et de l’ablation par radiofr quence pour traitement des tumeurs rénales chez les patients de plus de 75 ans [Comparison of operative and oncologic results between partial nephrectomy and radiofrequency ablation for treatment of renal tumors in patients older than 75]. Prog. Urol. 2018; 28 (1): 55–61. http://doi.org/10.1016/j.purol.2017.10.006Test (In French); Yan S., Yang W., Zhu C.M. et al. Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2–4 cm: A population-based study. Medicine (Baltimore). 2019; 98 (21): e15610. http://doi.org/10.1097/MD.0000000000015610Test; Rivero J.R., De La Cerda J. 3rd, Wang H. et al. Partial Nephrectomy versus Thermal Ablation for Clinical Stage T1 Renal Masses: Systematic Review and Meta-Analysis of More than 3,900 Patients. J. Vasc. Interv. Radiol. 2018; 29 (1): 18–29. http://doi.org/10.1016/j.jvir.2017.08.013Test; Uhlig J., Strauss A., Rücker G. et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. Eur. Radiol. 2019; 29 (3): 1293–1307. http://doi.org/10.1007/s00330-018-5660-3Test; Wilcox Vanden Berg R.N., Basourakos S.P., LaRussa S., McClure T.D. Management of the Small Renal Mass: a 2020 Update. Curr. Oncol. Rep. 2020; 22 (7): 69. http://doi.org/10.1007/s11912-020-00924-9Test; https://medvis.vidar.ru/jour/article/view/1309Test

الإتاحة: https://doi.org/10.24835/1607-0763-1244Test
https://doi.org/10.1038/s41598-017-15922-4Test
https://doi.org/10.32113/wcrj_20183_1013Test
https://doi.org/10.17650/1726-9776-2019-15-2-15-24Test
https://doi.org/10.3322/caac.21660Test
https://doi.org/10.1093/annonc/mdz056Test
https://doi.org/10.1111/j.1464-410X.2008.07770.xTest
https://doi.org/10.1016/j.juro.2006.07.144Test
https://doi.org/10.2214/ajr.185.1.01850064Test
https://doi.org/10.2214/ajr.185.1.01850072Test

المؤلفون: A. A. Gritskevich, A. Yu. Popov, I. G. Rusakov, E. K. Vozniy, V. A. Makarov, D. I. Gridnev, T. P. Baitman, S. V. Mishugin, I. V. Novikova, S. V. Khromova, А. А. Грицкевич, А. Ю. Попов, И. Г. Русаков, Э. К. Возный, В. А. Макаров, Д. И. Гриднев, Т. П. Байтман, С. В. Мишугин, И. В. Новикова, С. В. Хромова

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2022); 95-103 ; Медицинский Совет; № 9 (2022); 95-103 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: клинический случай, metastatic bladder cancer, vinflunin, chemotherapy, second line, clinical report, метастатический рак мочевого пузыря, винфлунин, химиотерапия, вторая линия

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/6922/6219Test; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.).Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.; 2021. 252 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf?ysclid=l3badk8twuTest.; Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet. Oncology. 2011;12(3):211—214. https://doi.org/10.1016/S1470-2045Test(10)70275-8.; Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy.J Clin Oncol. 2011;29(17):2432-2438. https://doi.org/10.1200/JCO.2011.34.8433Test.; Hussain S.A., Palmer D.H., Lloyd B., Collins S.I., Barton D., Ansari J., James N. D. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett. 2012;3(4):855-859. https://doi.org/10.3892/ol.2012.563Test.; Hussain S.A., Stocken D.D., Riley P., Palmer D.H., Peake D.R., Geh J.I. et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91(5):844-849. https://doi.org/10.1038/sj.bjc.6602112Test.; Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92(12):2993-2998. https//doi.org/10.1002/1097-0142(20011215)92:123.0.co;2-2.; Meluch A.A., Greco F.A., Burris H.A. 3rd, O'Rourke T., Ortega G., Steis R.G. et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19(12):3018-3024. https://doi.org/10.1200/JCO.2001.19.12.3018Test.; Calabro F., Lorusso V., Rosati G., Manzione L., Frassineti L., Sava T. et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652-2659. https://doi.org/10.1002/cncr.24313Test.; De Santis M., Wiechno P.J., Bellmunt J., Lucas C., Su W.C., Albiges L. et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016;27(3):449-454. https//doi.org/10.1093/annonc/mdv609.; Galsky M.D., Arija J., Bamias A., Davis I.D., De Santis M., Kikuchi E. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre,randomised,placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557. https//doi.org/10.1016/S0140-6736(20)30230-0.; Powles T., Csoszi T., Ozguroglu M., Matsubara N., Geczi L., Cheng S.Y. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931-945. https//doi.org/10.1016/S1470-2045(21)00152-2.; Powles T., van der Heijden M.S., Castellano D., Galsky M.D., Loriot Y., Petrylak D.P. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574-1588. https//doi.org/10.1016/S1470-2045(20)30541-6.; Oing C., Rink M., Oechsle K., Seidel C., von Amsberg G., Bokemeyer, C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195(2):254-263. https//doi.org/10.1016/j.juro.2015.06.115.; Raggi D., Miceli R., Sonpavde G., Giannatempo P., Mariani L., Galsky M.D. et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):49-61. https//doi.org/10.1093/annonc/mdv509.; Albers P., Park S.I., Niegisch G., Fechner G., Steiner U., Lehmann J. et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22(2):288-294. https://doi.org/10.1093/annonc/mdq398Test.; Fechner G., Siener R., Reimann M., Kobalz L., Albers P. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60(1):27-31. https//doi.org/10.1111/j.1742-1241.2005.00663.x.; Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-4461. https//doi.org/10.1200/JCO.2008.20.5534.; Жавлор: новые возможности в терапии больных метастатическим раком мочевого пузыря. Х Юбилейный конгресс Российского общества онкоурологов. Сателлитный симпозиум компании Pierre Fabre. Эффективная фармакотерапия. 2015;(3):34-38. Режим доступа: https://umedp.ru/upload/iblock/6a5/onko_03_2015.pdfTest.; Castellano D., Puente J., de Velasco G., Chirivella I., Lopez-Criado P., Mohedano N. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14:779. https://doi.org/10.1186/1471-2407-14-779Test.; Medioni J., Di Palma M., Guillot A., Spaeth D., Theodore C. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 2016;16:217. https://doi.org/10.1186/s12885-016-2262-9Test.; Retz M., de Geeter P., Goebell P.J., Matz U., de Schultz W., Hegele A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer. 2015;15:455. https://doi.org/10.1186/s12885-015-1434-3Test.; Волкова М.И., Черняев В.А., Матвеев В.Б., Алексеев Б.Я., Нюшко К.М., Болотина Л.В. и др. Эффективность и безопасность винфлунина во 2-й линии терапии у больных распространенным переходно-клеточным раком мочевых путей в клинической практике. Онкоурология. 2016;(3):74-81. https://doi.org/10.17650/1726-9776-2016-12-3-74-81Test.; https://www.med-sovet.pro/jour/article/view/6922Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-9-95-103Test
https://doi.org/10.1016/S1470-2045Test(10)70275-8
https://doi.org/10.1200/JCO.2011.34.8433Test
https://doi.org/10.3892/ol.2012.563Test
https://doi.org/10.1038/sj.bjc.6602112Test
https://doi.org/10.1002/1097-0142Test(20011215)92:12<2993::aid-cncr10108>3.0.co;2-2
https://doi.org/10.1200/JCO.2001.19.12.3018Test
https://doi.org/10.1002/cncr.24313Test
https://doi.org/10.1093/annonc/mdv609Test
https://doi.org/10.1016/S0140-6736Test(20)30230-0